All GLG News Analyses Filed Under: Ophthalmology

       Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label.   Although this amount of sales places Lucentis well within the blockbuster...

-Avastin has been repackaged by some compounding pharmacies in place of Lucentis for an indication for which Avastin is not approved.  They are both Genentech drugs, but with Lucentis being much more expensive.  -This is a bit like grinding up amoxicillin tablets, making them into a suspension,...

How much should packaging of a drug cost?

To delve further into the reasons for retinal ganglion cell death is critical for the future of glaucoma treatment. As the article discusses, there are reasons for retinal ganglion cell death other than high intraocular pressures.  Unfortunately, the only medical and surgical methods we have...

Alcon holds more than 70% of Wavelights shares and its takeover of Wavelight has been approved by the German authorities. WHile wavelight produces some interesting intraocular lenses, it is clear that Alcons interest in Wavelight lies in its realiable and fast excimer laser system that can be used for...

New research indicating the presence of amyloid-beta protein in dying retinal cells  suggests a new direction in glaucoma research. Amyloid-beta is a protein found in Alzheimer's plaques. Using a rat model of glaucoma, the researchers found that the dying retinal cells showed accumulation of amyloid-beta....

LX211, calcineurin inhibitor and antiinflammatory drug, was granted Fast Track designation by the FDA. This move could expedite its approval for the management of non-infectious posterior, intermediate and panuveitis. In a field where there are few approved treatment modalities, this could be very big...

So how important is contact lens hygiene?  Extremely.  If you don't properly take care of your contact lenses, you risk vision loss. Would you change your bad habits if it were to cost you your professional career?  Most sane, competent people would emphatically say 'YES!'. ...

AMO has come out with a "new" product to be released in Sept 2007. But they have not announced what the key active ingredient is. The active ingredient(disinfectant) can determine where it stands compared to other products available on the market in the US. I list most of the various contact lens care...

How did AMO develop a novel contact lens solution so quickly? Is this really a brand new formula? How will AMO regain the confidence of eye care professionals and the public with regard to their contact lens related products?